Several studies have reported that the nuclear translocation of CDK5 inhibits the proliferation and tumorigenicity of cancer cells, and CDK5 inhibitors (roscovitine) interfere with the nuclear translocation of CDK5 from the cytoplasm during the phosphorylation of p53 by CDK5.34, 35, 36. Here, CDK5 is linked to cancer.